Pulmobiotics develops novel live biotherapeutics specifically targeting respiratory diseases. The company utilizes a proprietary genetic toolkit and genome editing technology to modify bacteria for therapeutic use. This approach aims to provide new solutions for various debilitating lung conditions.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Respiratory diseases, including antibiotic-resistant lung infections, are a leading cause of death worldwide. Current treatments often lack targeted delivery and struggle to overcome increasing antibiotic resistance, resulting in high mortality rates.
Solution
Pulmobiotics is developing live biotherapeutics using a proprietary genetic toolkit to target and treat respiratory diseases. Their approach involves genetically modifying bacteria to deliver therapeutic payloads directly to the lungs, offering a novel method to combat antibiotic-resistant infections. The company's platform allows for the adaptation of genome editing tools to modify the genome of different bacteria, creating tailored treatments for various lung conditions. This targeted delivery system aims to improve treatment efficacy and reduce mortality associated with severe respiratory illnesses.
Target Audience
The primary target audience includes patients suffering from respiratory diseases, particularly antibiotic-resistant lung infections, and the healthcare providers who treat them.
Features
- Proprietary genetic toolkit for engineering live biotherapeutics
- Genome editing tools adaptable to modify the genome of different bacteria
- Targeted delivery of therapeutics directly to the lungs
- Focus on treating antibiotic-resistant lung infections and other respiratory diseases